The most compelling evidence is the interim results from the latest Randomised Controlled Trial in America.

10 patients were monitored after release from A&E with a urinary catheter, the average age was 63.5 (high – 82, low – 27)

Foley catheters with UroShield maintained urine sterility for up to 9 days compared to 2 days in control catheterized animals.

Not only have SAW been shown to reduce CAUTI development and increase antibiotic efficacy, but there has now been the first report of SAW affecting cell signalling via integrins.

In double-blinded randomized control trial, of Uroshield, 55 patients in a skilled nursing facility chain who were being treated with long-term indwelling catheters were evaluated. There was a significant difference between the treated group and the placebo group in the number of CFU, as well as on the number of treated UTIs.